Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

Haematologica. 2016 Jul;101(7):e295-8. doi: 10.3324/haematol.2015.140806. Epub 2016 May 5.

¹ Dana-Farber Cancer Institute, Boston, MA, USA jennifer_brown@dfci.harvard.edu.
² Horizon Oncology Center, Lafayette, IN, USA.
³ Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, OH, USA.
⁴ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁵ Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR, USA.
⁶ Clearview Cancer Institute, Huntsville, AL, USA.
⁷ Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, USA.
⁸ Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
⁹ University of Arizona Cancer Center, Tucson, AZ, USA.
¹⁰ Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, USA.
¹¹ University of Texas Health Science Center at San Antonio, CTRC Institute for Drug Development, TX, USA.
¹² The West Clinic, University of Tennessee Health Sciences Center, ACORN Research, LLC, Memphis, TN, USA.
¹³ Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
¹⁴ Department of Translational Medicine, Celgene Corporation, San Francisco, CA, USA.
¹⁵ Celgene Corporation, Summit, NJ, USA.
¹⁶ Celgene Corporation, Berkeley Heights, NJ, USA.
¹⁷ University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA.

No abstract available

Keywords: BTK inhibitors; CC-292; chronic lymphocytic leukemia; refractory; relapsed; single-agent; small lymphocytic lymphoma.

Publication types